Your browser doesn't support javascript.
loading
Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol.
den Hollander, Dide; Fiore, Marco; Martin-Broto, Javier; Kasper, Bernd; Casado Herraez, Antonio; Kulis, Dagmara; Nixon, Ioanna; Sodergren, Samantha C; Eichler, Martin; van Houdt, Winan J; Desar, Ingrid M E; Ray-Coquard, Isabelle; Piccinin, Claire; Kosela-Paterczyk, Hanna; Miah, Aisha; Hentschel, Leopold; Singer, Susanne; Wilson, Roger; van der Graaf, Winette T A; Husson, Olga.
Affiliation
  • den Hollander D; Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Fiore M; Department of Medical Oncology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.
  • Martin-Broto J; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Kasper B; Department of Medical Oncology, Virgen del Rocío University Hospital, 41013 Sevilla, Spain.
  • Casado Herraez A; Sarcoma Unit, University of Heidelberg, Mannheim University Medical Center, 68167 Mannheim, Germany.
  • Kulis D; Department of Medical Oncology, Hospital Clínico San Carlos, 28040 Madrid, Spain.
  • Nixon I; Quality of Life Department, European Organisation for Research and Treatment of Cancer, 1200 Brussels, Belgium.
  • Sodergren SC; Department of Clinical Oncology, The Beatson Cancer Center, Glasgow G12 0YN, UK.
  • Eichler M; School of Health Sciences, University of Southampton, Southampton SO17 1BJ, UK.
  • van Houdt WJ; University Cancer Center (NCT/UCC), University Hospital Carl Gustav Carus, Technical University Dresden, 01069 Dresden, Germany.
  • Desar IME; Department of Surgical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
  • Ray-Coquard I; Department of Medical Oncology, Radboud University Medical Centre, 6525 GA Nijmegen, The Netherlands.
  • Piccinin C; HESPER Lab, Department of Medical Oncology, Centre Léon-Bérard, University Claude Bernard Lyon, 69008 Lyon, France.
  • Kosela-Paterczyk H; Quality of Life Department, European Organisation for Research and Treatment of Cancer, 1200 Brussels, Belgium.
  • Miah A; Department of Medical Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-034 Warsaw, Poland.
  • Hentschel L; Department of Clinical Oncology, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Singer S; University Cancer Center (NCT/UCC), University Hospital Carl Gustav Carus, Technical University Dresden, 01069 Dresden, Germany.
  • Wilson R; Epidemiology and Informatics, Institute of Medical Biostatistics, University Medical Centre Mainz, 55131 Mainz, Germany.
  • van der Graaf WTA; University Cancer Centre Mainz (UCT), University Medical Centre Mainz, 55131 Mainz, Germany.
  • Husson O; Sarcoma Patients EuroNet, D-85521 Riemerling, Germany.
Cancers (Basel) ; 13(1)2020 Dec 22.
Article de En | MEDLINE | ID: mdl-33561018
ABSTRACT
Sarcomas comprise 1% of adult tumors and are very heterogeneous. Long-lasting and cumulative treatment side-effects detract from the (progression-free) survival benefit of treatment. Therefore, it is important to assess treatment effectiveness in terms of patient-reported outcomes (PROs), including health-related quality of life (HRQoL) as well. However, questionnaires capturing the unique issues of sarcoma patients are currently lacking. Given the heterogeneity of the disease, the development of such an instrument may be challenging. The study aims to (1) develop an exhaustive list of all HRQoL issues relevant to sarcoma patients and determine content validity; (2) determine a strategy for HRQoL measurement in sarcoma patients. We will conduct an international, multicenter, mixed-methods study (registered at clinicaltrials.gov NCT04071704) among bone or soft tissue sarcoma patients ≥18 years, using EORTC Quality of Life Group questionnaire development guidelines. First, an exhaustive list of HRQoL issues will be generated, derived from literature and patient (n = 154) and healthcare professional (HCP) interviews (n = 30). Subsequently, another group of sarcoma patients (n = 475) and HCPs (n = 30) will be asked to rate and prioritize the issues. Responses will be analyzed by priority, prevalence and range of responses for each item. The outcome will be a framework for tailored HRQoL measurement in sarcoma patients, taking into account sociodemographic and clinical variables.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Guideline / Qualitative_research / Risk_factors_studies Aspects: Patient_preference Langue: En Journal: Cancers (Basel) Année: 2020 Type de document: Article Pays d'affiliation: Pays-Bas

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials / Guideline / Qualitative_research / Risk_factors_studies Aspects: Patient_preference Langue: En Journal: Cancers (Basel) Année: 2020 Type de document: Article Pays d'affiliation: Pays-Bas